 | Up a level |
Benito-Villalvilla, Cristina; de la Rocha-Muñoz, Andrés; López-Abente, Jacobo; Eggel, Alexander; Bottoli, Iván; Severin, Thomas; Woisetschläger, Maximilian; Palomares, Oscar (2023). Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation. Allergy, 78(4), pp. 1060-1072. Wiley 10.1111/all.15567
